While the majority of the adults infected with hepatitis C virus are baby boomers-people between the ages of 51 and 71 years-Alaska is seeing a large spike in infection rates among young adults.
While the majority of the adults infected with hepatitis C virus (HCV) are baby boomers—people between the ages of 51 and 71 years—Alaska is seeing a large spike in infection rates among young adults.
A bulletin published by the State of Alaska Section of Epidemiology reported that there have been large increases of HCV infection rates among 18- to 29-year-olds. The largest reported change was an increase of 490% from 2011 to 2015 in southeastern Alaska. The gulf coast region of Alaska had the smallest change, but still reported an increase of 45%.
According to the bulletin, injection drug use (IDU) among young adults is likely the cause of the rising number of HCV-infected individuals between the ages of 18 and 29.
“Previous Alaska data on HCV prevalence demonstrated the majority of HCV cases reported were among ‘baby boomers,’” the authors of the report wrote. “The recent increase in HCV among young adults follows national HCV trends and we presume that our HCV-infected young adults share similar IDU risk factors.”
Although the number of reported HCV cases rose considerably across all age groups from 2011 to 2015 in Alaska, the increase was proportionally highest among young adults. In 2011, young adults represented 22% of all newly reported HCV cases, but in 2015, they represented 31% of new cases.
In addition, the Section of Epidemiology found that while most cases of new HCV infection across all age groups were in males, among young adults, females represented the most cases of new HCV infection.
The report noted that one of the ways to decrease IDU, and HCV infection, is through the use of syringe exchange programs.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More